|
Aurora Fine Chemicals Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FRAGMENT LIBRARY Last Update: Feb 03, 2012 |
Aurora’s Fragment Library provides fragments binding to any targets which are crucial to drug discovery efforts. Fragment-based lead strategy is a relatively new approach in drug discovery wherein the small molecules of molecular weight between 100Da and 300Da are in use. Although Fragment-based hits are weak inhibitors they possess high ligand efficiency (binding affinity per heavy atom) and thus are highly suitable for optimization into clinical candidates with good drug-like properties.
|
||||||||||||||||||||||||||||||||||||||||||||||||
DISEASE TARGETED COMPOUND LIBRARIES Last Update: Feb 3, 2012 |
Based on the target protein and Aurora's drug like collection of small molecules the focused compound libraries are created (see table below). The libraries have been designed using molecular docking to specific proteins related to disease. The compounds were selected as per the pharmacokinetic parameters (ADME), solubility, docking score, intermolecular hydrogen bonds detection and other parameters. For neurological diseases just the compounds capable to cross the blood brain barrier were evaluated. All compounds are available in stock within 1-2 weeks.
i Binding Free Energy calculated by Aurora's software include intermolecular, internal and torsional energy.
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright Aurora Fine Chemicals Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||